News AbiVax claims progress towards HIV cure French biotech to step up clinical development of ABX464.
News Janssen axes hep C development with Achillion Johnson & Johnson has ended a collaboration with US biotech Achillion to develop hepatitis C drugs, sending the US biotech firm's shares plummeting.
News Regeneron ends development of RSV antibody Regeneron dumps suptavumab after phase 3 trial failure.
News Vernalis shares slide after latest FDA rejection Shares in UK pharma Vernalis slid more than 15% after the US regulator rejected its cough and cold treatment, known as CCP-08.
News AbbVie, Gilead target sick hepatitis C patients in EU Competing hepatitis C combination drugs from AbbVie and Gilead are now approved in the EU, as the companies aim to treat patients who cannot be cured with established regimens.
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
